Beckley Psytech has announced a new clinical trial investigating its novel formulation of the psychedelic drug DMT for the treatment of depression.
In a new brain-imaging study, UK researchers will explore how DMT impacts brain function, behaviour and well-being.
Researchers at Johns Hopkins Medicine have found that just a single psychedelic experience may increase a range of beliefs about consciousness, meaning and purpose.
Biopharmaceutical company, Silo Pharma, has announced plans to study its novel joint homing peptide in the treatment of rheumatoid arthritis.
MAPS has announced further developments in its Phase 3 study of MDMA-assisted therapy for the treatment of PTSD.
